The smarter E Europe: Smart Integration Saves Cash and Stabilizes Grids
12.2.2025 17:52:00 CET | Business Wire | Press release
‘Accelerating Integrated Energy Solutions’ - this is the motto of The smarter E Europe 2025, which will take place this year from 7 to 9 May at Messe München.Smart integration is crucial in the evolving energy and mobility sectors. Energy management systems (EMS) for prosumers and businesses have shifted from a nice-to-have to a must-have, making them a key topic at this year’s event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250212149082/en/
At The smarter E Europe 2025, visitors will find everything for the smart interaction of PV, storage, e-mobility and energy management. (Photo: Solar Promotion GmbH)
GridX, a smart energy company, estimates that the European Home Energy Management System (HEMS) market will expand 11-fold by 2030 across Denmark, Germany, the UK, Italy, the Netherlands, Austria, Sweden, and Spain. This rapid growth reflects increasing demand and evolving regulations.
Regulatory and market requirements
Regulations such as Section 14a of Germany’s Energy Industry Act (EnWG) allow grid operators to control the power output of heat pumps, EV chargers, and battery storage systems. A robust EMS can optimize energy use, reducing reliance on the grid without compromising user comfort.
The challenge of interoperability
Interoperability remains a challenge, with ongoing discussions about standardization. Manufacturer-independent solutions allow greater flexibility for customers. At The smarter E Europe, top industry leaders will address interoperability concerns, emphasizing open standards. In 2018, the OpenEMS Association took a leading role in supporting efforts to create open and manufacturer-independent standards for energy management systems. OpenEMS is not a communication protocol, such as EEBus, but a software platform. The Association counts universities and research institutes, grid operators and industry associations as well as energy management companies among its members.
Focus event hosted by pv magazine and The smarter E Forum
Home energy management is also going to be discussed at the focus event hosted by pv magazine on the second exhibition day, May 8, 2025. Two interactive sessions will shed light on key aspects of quality photovoltaics and storage projects in the small and utility-scale sectors. pv magazine invites interested visitors to ICM – International Congress Center Messe München, room 13, from 1:00pm–5:00pm. It will be held in German. A separate, English-speaking session aimed at an international expert audience will focus on optimizing large-scale storage systems and the quality assurance of planning, design and marketing. Click here to register for the event.
The smarter E Forum will be organizing a dedicated session for prosumer home energy management systems. On Friday, May 9, the key role of HEMS for modern energy management and grid stability will be discussed starting from 1:30pm.
Munich becomes the center of the energy world
In May, at Messe München, innovation will meet practice, and visions will meet concrete solutions. The smarter E Europe shows how the sectors electricity, heat and transportation can be intelligently connected to create a decentralized, digitalized and flexible energy world. From May 7–9, 2025, Messe München is fully booked – the organizers expect more than 3,000 exhibitors and over 110,000 visitors at the exhibition ground covering 206,000 square meters across 19 exhibition halls and the Outdoor Area.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212149082/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom